Heterogeneity of outcomes of endometrial cancer patients included in prospective clinical trials

Objective. To assess heterogeneity in five-year overall survival of patients with endometrial cancer using a large retrospective database with cohorts defined by recent prospective clinical trials. Methods. The National Cancer Database was used to identify patients with endometrial cancer who under-went hysterectomy from 2004 to 2016. The reported inclusion criteria for GOG-249, PORTEC-3, and GOG-258 were used to define the respective cohorts. Five-year overall survival for each cohort was stratified by tumor characteristics and adjuvant therapy regimens.Results. A total of 89,133 patients were identified who would have fulfilled the entry criteria to GOG-249, PORTEC-3, or GOG-258. When stratified by tumor characteristics, irrespective of adjuvant therapy, five-year overall survival ranged from 59.9%-81.7% for patients meeting GOG-249 inclusion criteria, 40.2%-81.8% for pa-tients meeting PORTEC-3 inclusion criteria, and 17.5%-75.0% for those meeting GOG-258 inclusion criteria. Anal-ysis of subgroups by adjuvant therapy regimen revealed significant improvement in five-year overall survival for chemoradiotherapy compared to chemotherapy or radiotherapy alone for endometroid stage III and stage IVA disease and for some stages of serous and clear cell histology.Conclusions. Recent prospective trials of adjuvant therapy for endometrial cancer have included heteroge-neous cohorts of patients based on five-year overall survival rates when the populations are stratified by tumor characteristics. The variation in expected five-year overall survival for subsets of patients may result in underpowered studies or misleading results.(c) 2022 Elsevier Inc. All rights reserved.

Automated summary

This study assessed heterogeneity in five-year overall survival of patients with endometrial cancer using a large retrospective database. Cohorts were defined based on recent prospective clinical trials. The results showed significant variation in five-year overall survival among different cohorts based on tumor characteristics and adjuvant therapy regimens. The variation in expected survival rates for subsets of patients may lead to underpowered studies or misleading results.